Baseline plasma C-reactive protein concentrations and motor prognosis in Parkinson disease

PLoS ONE

Volumn 10, Issue 8, 2015, Pages

  Umemura, Atsushi ^a   Oeda, Tomoko ^a   Yamamoto, Kenji ^a   Tomita, Satoshi ^a   Kohsaka, Masayuki ^a   Park, Kwiyoung ^a   Sugiyama, Hiroshi ^a   Sawada, Hideyuki ^a  

^a UTANO NATIONAL HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; C REACTIVE PROTEIN; DOPAMINE RECEPTOR STIMULATING AGENT; ENTACAPONE; LEVODOPA; SELEGILINE; AUTACOID; BIOLOGICAL MARKER;

ADULT; AGED; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DEMENTIA; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL DETERIORATION; PARKINSON DISEASE; PROGNOSIS; PROTEIN BLOOD LEVEL; RETROSPECTIVE STUDY; UNIFIED PARKINSON DISEASE RATING SCALE; BLOOD; CASE CONTROL STUDY; COMPARATIVE STUDY; COMPLICATION; DISEASE COURSE; LONGITUDINAL STUDY; MIDDLE AGED; MOTOR ACTIVITY; PATHOLOGY;

AGED; BIOMARKERS; C-REACTIVE PROTEIN; CASE-CONTROL STUDIES; DEMENTIA; DISEASE PROGRESSION; FEMALE; HUMANS; INFLAMMATION MEDIATORS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; MOTOR ACTIVITY; PARKINSON DISEASE; PROGNOSIS; RETROSPECTIVE STUDIES;

EID: 84943262772     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0136722     Document Type: Article

References (41)

1. Macchi B, Di Paola R, Marino-Merlo F, Felice MR, Cuzzocrea S, Mastino A. Inflammatory and cell death pathways in brain and peripheral blood in Parkinson's disease. CNS Neurol Disord Drug Targets. 2015; 14:313-324. PMID: 25714978
2. McGeer PL, McGeer EG. Inflammation and neurodegeneration in Parkinson's disease. Parkinsonism Relat Disord. 2004; 10 Suppl 1:S3-S7. PMID: 15109580
3. Hirsch EC, Breidert T, Rousselet E, Hunot S, Hartmann A, Michel PP. The role of glial reaction and inflammation in Parkinson's disease. Ann NY Acad Sci. 2003; 991:214-228. PMID: 12846989
4. Codolo G, Plotegher N, Pozzobon T, Brucale M, Tessari I, Bubacco L, et al. Triggering of inflammasome by aggregated α-synuclein, an inflammatory response in synucleinopathies. PLoS One. 2013; 8: e55375. doi: 10.1371/journal.pone.0055375 PMID: 23383169
5. Pott Godoy MC, Ferrari CC, Pitossi FJ. Nigral neurodegeneration triggered by striatal AdIL-1 administration can be exacerbated by systemic IL-1 expression. J Neuroimmunol. 2010; 222:29-39. doi: 10. 1016/j.jneuroim.2010.02.018 PMID: 20350768
6. Koprich JB, Reske-Nielsen C, Mithal P, Isacson O. Neuroinflammation mediated by IL-1β increases susceptibility of dopamine neurons to degeneration in an animal model of Parkinson's disease. J Neuroinflammation. 2008; 5:8. doi: 10.1186/1742-2094-5-8 PMID: 18304357
7. Pott Godoy MC, Tarelli R, Ferrari CC, Sarchi MI, Pitossi FJ. Central and systemic IL-1 exacerbates neurodegeneration and motor symptoms in a model of Parkinson's disease. Brain. 2008; 131:1880-1894. doi: 10.1093/brain/awn101 PMID: 18504291
8. Villarán RF, Espinosa-Oliva AM, Sarmiento M, De Pablos RM, Arguelles S, Delgado-Cortes MJ, et al. Ulcerative colitis exacerbates lipopolysaccharide-induced damage to the nigral dopaminergic system: potential risk factor in Parkinson's disease. J Neurochem. 2010; 114:1687-1700. doi: 10.1111/j.1471- 4159.2010.06879.x PMID: 20584104
9. Umemura A, Oeda T, Tomita S, Hayashi R, Kohsaka M, Park K, et al. Delirium and high fever are associated with subacute motor deterioration in Parkinson disease: a nested case-control study. PLoS One. 2014; 9:e94944. doi: 10.1371/journal.pone.0094944 PMID: 24887491
10. Schmidt R, Schmidt H, Curb JD, Masaki K, White LR, Launer LJ. Early inflammation and dementia: a 25-year follow-up of the Honolulu-Asia Aging Study. Ann Neurol. 2002; 52:168-174. PMID: 12210786
11. Tan ZS, Beiser AS, Vasan RS, Roubenoff R, Dinarello CA, Harris TB, et al. Inflammatory markers and the risk of Alzheimer disease: the Framingham Study. Neurology. 2007; 68:1902-1908. PMID: 17536046
12. Closhen D, Bender B, Luhmann HJ, Kuhlmann CR. CRP-induced levels of oxidative stress are higher in brain than aortic endothelial cells. Cytokine. 2010; 50: 117-120. doi: 10.1016/j.cyto.2010.02.011 PMID: 20207160
13. Li YN, Qin XJ, Kuang F, Wu R, Duan XL, Ju G, et al. Alterations of Fc gamma receptor I and Toll-like receptor 4 mediate the antiinflammatory actions of microglia and astrocytes after adrenaline-induced blood-brain barrier opening in rats. J Neurosci Res 2008; 86:3556-3565. doi: 10.1002/jnr.21810 PMID: 18756515
14. Yasojima K, Schwab C, McGeer EG, McGeer PL. Human neurons generate C-reactive protein and amyloid P: upregulation in Alzheimer's disease. Brain Res. 2000; 887:80-89. PMID: 11134592
15. McGeer PL, McGeer EG, Yasojima K. Alzheimer disease and neuroinflammation. J Neural Transm Suppl. 2000; 59:53-57. PMID: 10961418
16. Roubenoff R, Harris TB, Abad LW, Wilson PW, Dallal GE, Dinarello CA. Monocyte cytokine production in an elderly population: effect of age and inflammation. J Gerontol A Biol Sci Med Sci. 1998; 53:M20-M26. PMID: 9467429
17. Haider DG, Leuchten N, Schaller G, Gouya G, Kolodjaschna J, Schmetterer L, et al. C-reactive protein is expressed and secreted by peripheral blood mononuclear cells. Clin Exp Immunol, 2006; 146:533-539. PMID: 17100775
18. Mortensen RF, Zhong W. Regulation of phagocytic leukocyte activities by C-reactive protein. J Leukoc Biol. 2000; 67:495-500. PMID: 10770281
19. Emberson JR, Whincup PH, Morris RW, Walker M, Lowe GD, Rumley A. Extent of regression dilution for established and novel coronary risk factors: results from the British Regional Heart Study. Eur J Cardiovasc Prev Rehabil. 2004; 11:125-134. PMID: 15187816
20. Shulman LM, Gruber-Baldini AL, Anderson KE, Fishman PS, Reich SG, Weiner WJ. The clinically important difference on the unified Parkinson's disease rating scale. Arch Neurol. 2010; 67:64-70. doi: 10.1001/archneurol.2009.295 PMID: 20065131
21. Parashos SA, Luo S, Biglan KM, Bodis-Wollner I, He B, Liang GS, et al. NET-PD Investigators. Measuring disease progression in early Parkinson disease: the National Institutes of Health Exploratory Trials in Parkinson Disease (NET-PD) experience. JAMA Neurol. 2014; 71:710-716. doi: 10.1001/ jamaneurol.2014.391 PMID: 24711047
22. Daniel SE, Lees AJ. Parkinson's Disease Society Brain Bank, London: overview and research. J Neural Transm Suppl. 1993; 39: 165-172. PMID: 8360656
23. Mckeith IG, Dickson DW, Lowe J, Emre M, O'Brien JT, Feldman H, et al. Consortium on DLB. Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology. 2005; 65:1863-1872. PMID: 16237129
24. Tomlinson CL, Stowe R, Patel S, Rick C, Gray R, Clarke CE. Systematic review of levodopa dose equivalency reporting in Parkinson's disease. Mov Disord. 2010; 25:2649-2653. doi: 10.1002/mds. 23429 PMID: 21069833
25. American Psychiatry Association. Diagnostic and Statistical Manual of Mental Disorders: DSM-IV-TR. Washington DC: American Psychiatry Association; 2000.
26. Alves G, Wentzel-Larsen T, Aarsland D, Larsen JP. Progression of motor impairment and disability in Parkinson disease: a population-based study. Neurology. 2005; 65:1436-1441. PMID: 16275832
27. Zeger SL, Liang KY, Albert PS. Models for longitudinal data: a generalized estimating equation approach. Biometrics. 1988; 44:1049-1060. PMID: 3233245
28. McCullagh P, Nelder J. Generalized linear models, 2nd edition. London: Chapman and Hall; 1989.
29. Zhang L, Yan J, Xu Y, Long L, Zhu C, Chen X, et al. The combination of homocysteine and C-reactive protein predicts the outcomes of Chinese patients with Parkinson's disease and vascular parkinsonism. PLoS One. 2011; 6:e19333. doi: 10.1371/journal.pone.0019333 PMID: 21556377
30. Hassin-Baer S, Cohen OS, Vakil E, Molshazki N, Sela BA, Nitsan Z, et al. Is C-reactive protein level a marker of advanced motor and neuropsychiatric complications in Parkinson's disease? J Neural Transm. 2011; 118:539-543. doi: 10.1007/s00702-010-0535-z PMID: 21161711
31. Suk HJ, Ridker PM, Cook NR, Zee RY. Relation of polymorphism within the C-reactive protein gene and plasma CRP levels. Atherosclerosis. 2005; 178:139-145. PMID: 15585211
32. Sawada H, Oeda T, Umemura A, Tomita S, Hayashi R, Kohsaka M, et al. Subclinical elevation of plasma C-reactive protein and illusions/hallucinations in subjects with Parkinson's disease: case-control study. PLoS One. 2014; 9:e85886. doi: 10.1371/journal.pone.0085886 PMID: 24497930
33. Scalzo P, Kümmer A, Cardoso F, Teixeira AL. Serum levels of interleukin-6 are elevated in patients with Parkinson's disease and correlate with physical performance. Neurosci Lett. 2010; 468:56-58. doi: 10.1016/j.neulet.2009.10.062 PMID: 19857551
34. Lindqvist D, Kaufman E, Brundin L, Hall S, Surova Y, Hansson O. Non-motor symptoms in patients with Parkinson's disease-correlations with inflammatory cytokines in serum. PLoS One. 2012; 7:e47387. doi: 10.1371/journal.pone.0047387 PMID: 23082161
35. Dursun E, Gezen-Ak D, Hanagasi H, Bilgiç B, Lohmann E, Ertan S, et al. The interleukin 1 alpha, interleukin 1 beta, interleukin 6 and alpha-2-macroglobulin serum levels in patients with early or late onset Alzheimer's disease, mild cognitive impairment or Parkinson's disease. J Neuroimmunol. 2015; 283:50-57. doi: 10.1016/j.neuroim.2015.04.014 PMID: 26004156
36. Chen H, O'Reilly EJ, Schwarzschild MA, Ascherio A. Peripheral inflammatory biomarkers and risk of Parkinson's disease. Am J Epidemiol, 2008; 167:90-95. PMID: 17890755
37. Taniguchi A, Narita Y, Naito Y, Kuzuhara S. Analysis of application form for Parkinson's disease provided by the specific diseases treatment research program of Ministry of Health, Labour and Welfare of Japan. Rinsho Shinkeigaku. 2008; 48:106-113 (in Japanese). PMID: 18326303
38. Kimura H, Kato T. Epidemiology of Parkinson's disease. Sogo Rinsho. 2010; 59:2371-2376 (in Japanese).
39. Haaxma CA, Bloem BR, Borm GF, Oyen WJ, Leenders KL, Eshuis S, et al. Gender differences in Parkinson's disease. J Neurol Neurosurg Psychiatry. 2007; 78:819-824. PMID: 17098842
40. Wirdefeldt K, Adami HO, Cole P, Trichopoulos D, Mandel J. Epidemiology and etiology of Parkinson's disease: a review of the evidence. Eur J Epidemiol. 2011; 26 Suppl 1:S1-S58. doi: 10.1007/s10654-011-9581-6 PMID: 21626386
41. Marras C, Rochon P, Lang AE. Predicting motor decline and disability in Parkinson disease: a systematic review. Arch Neurol. 2002; 59:1724-1728. PMID: 12433259